The market for orlistat is expected to develop significantly as a result of increased weight control awareness programmes. For instance, the pharmaceutical company Roche Holding AG launched its 'New You Weight Consciousness Advocacy Campaign' in 2013 with the intention of increasing public awareness of obesity and the available treatments. Such awareness campaigns are expected to encourage the use of weight-loss medications, which is expected to hasten the market expansion for orlistat.
It is projected that the re-release of Orlistat products will accelerate market growth. For instance, in February 2018, H2 Pharma, LLC and Cheplapharma Arzneimittel GmbH worked together to relaunch Xenical Capsules that had been acquired from F. Hoffman-La Roche.
The global Orlistat Market was estimated to be worth USD 3.02 billion in 2021 and is anticipated to grow at a CAGR of 6.2% to reach USD 4.61 billion by the year 2028.
Prominent Companies in the Orlistat Industry:
1. Creator of products and technologies based on nucleic acids. The business is involved in the creation of prescription medications. United States headquarters. Established on October 1st, 1896. Roche and Janssen strengthen their partnership to improve individualised healthcare through companion diagnostics.
Roche Holding AG:
2. By overall sales, GSK is one of the biggest companies in the pharmaceutical sector. The corporation exercises its influence in a number of therapeutic areas, including vaccines, cancer, antiviral, and respiratory treatments. GSK employs collaborative ventures to increase its market share in niche sectors like the HIV market. Established in 2000. Located in England, in the United Kingdom. A deal has been reached for GSK to purchase the late-stage biopharmaceutical business BELLUS Health.